News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

FYI From Human Genome Sciences, Inc. (HGSI): GlaxoSmithKline (GSK) Announces Positive Data from Harmony 8 Phase 3 Trial and Completion of Clinical Registration Package for Albiglutide in Type 2 Diabetes


7/11/2012 10:09:28 AM

ROCKVILLE, Md.--(BUSINESS WIRE)--Attached is a press release issued earlier today by GlaxoSmithKline, announcing that data have been received from the Phase 3 Harmony 8 study and from the event-driven meta-analysis for assessment of cardiovascular safety conducted across the albiglutide clinical program in type 2 diabetes. These data are the final elements required to complete the clinical registration package.

Read at BioSpace.com


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES